Fig. 1 | Oncogene

Fig. 1

From: Gene activation of CEBPA using saRNA: preclinical studies of the first in human saRNA drug candidate for liver cancer

Fig. 1

Transcriptional activity of CEBPA-51 in vitro. a CEBPA-51 saRNA transfection increases CEBPA mRNA in murine AML12, Rattus (Clone 9), Human (HEPG2) and human (Primary hepatocytes). Key factors for liver function were screened in CEBPA-51 transfected primary human hepatocytes. These included b albumin, HNF4A (Hepatocyte nuclear factor 4-alpha), and CYP3A4 (Cytochrome P450 3A4). Data are expressed as mean ± SEM. ¥ = p( < 0.00027) and * = p(0.0033). c A western blot panel probed with antibody specific to HNF4A (Abcam; ab41898), CYP3A4 (Abcam; ab155029), Albumin (Abcam; ab106582), and CEBPA (CELL Signalling; 8178) showed visible increase in protein expression in cells transfected with CEBPA-51. Actin expression (Abcam: ab8226) was used as protein loading control across each of the lanes

Back to article page